Investor disappointment earlier this month regarding positive – but apparently not positive enough – Phase III results with Insmed Inc.'s antibiotic candidate seemed to be turning around on word that the company is netting $58 million in a stock sale to help push Arikace to the finish line. Read More
If a compounding pharmacy looks like a drug manufacturer, walks like a drug manufacturer and quacks like a drug manufacturer, it should be regulated like a drug manufacturer. Read More
Using the gene that normally shuts off one X chromosome in females, researchers have managed to silence the extra copy of chromosome 21 in induced pluripotent stem cells (iPSCs) from Down syndrome patients. Read More
A new public offering of 4.5 million shares of common stock at $9.50 per share will help to float Regulus Therapeutics Inc.'s pipeline of drugs targeting microRNAs, including its lead compound RG-101 for hepatitis C virus. The offering is expected to raise gross proceeds of $42.8 million, and will close on or about July 22. Read More
An emergency committee convened by World Health Organization (WHO) director-general, Margaret Chan, concluded that at this point, the Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) does not warrant being declared a public health emergency of international concern. Read More
• Biospecifics Technologies Corp., of Lynbrook, N.Y., said its partner Auxilium Pharmaceuticals Inc., of Malvern, Pa., has entered a collaboration with Swedish Orphan Biovitrum AB (Sobi), of Stockholm, for the long-term development, supply and commercialization of Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture. Read More
• Synergy Pharmaceuticals Inc., of New York, reached the halfway mark for total enrollment in an ongoing Phase II trial of plecanatide in patients with irritable bowel syndrome with constipation. Read More
• Sihuan Pharmaceutical Holdings Group Ltd., of Hong Kong, said anaprazole sodium, received the approval for clinical studies from the CFDA. Anaprazole sodium is a new generation of proton pump inhibitors (PPIs) for treating ulcers by inhibiting gastric acid secretion and eradicating Helicobacter pylori. Read More
• Basilea Pharmaceutica Ltd., of Basel, Switzerland, said topline data from the SECURE and VITAL Phase III studies are on track to be available in the second half of 2013. Read More
